270 related articles for article (PubMed ID: 20230194)
1. Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development.
Barry ER; Corry GN; Rasmussen TP
Expert Opin Ther Targets; 2010 Apr; 14(4):405-18. PubMed ID: 20230194
[TBL] [Abstract][Full Text] [Related]
2. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Chen CW; Armstrong SA
Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
[TBL] [Abstract][Full Text] [Related]
3. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications.
Milne TA; Martin ME; Brock HW; Slany RK; Hess JL
Cancer Res; 2005 Dec; 65(24):11367-74. PubMed ID: 16357144
[TBL] [Abstract][Full Text] [Related]
4. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
Deshpande AJ; Chen L; Fazio M; Sinha AU; Bernt KM; Banka D; Dias S; Chang J; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
Blood; 2013 Mar; 121(13):2533-41. PubMed ID: 23361907
[TBL] [Abstract][Full Text] [Related]
5. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
Nguyen AT; Taranova O; He J; Zhang Y
Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783
[TBL] [Abstract][Full Text] [Related]
6. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
Yokoyama A; Somervaille TC; Smith KS; Rozenblatt-Rosen O; Meyerson M; Cleary ML
Cell; 2005 Oct; 123(2):207-18. PubMed ID: 16239140
[TBL] [Abstract][Full Text] [Related]
7. Reconstructing the disease model and epigenetic networks for MLL-AF4 leukemia.
Zeisig BB; Cheung N; Yeung J; So CW
Cancer Cell; 2008 Nov; 14(5):345-7. PubMed ID: 18977321
[TBL] [Abstract][Full Text] [Related]
8. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
9. Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia.
Barve A; Vega A; Shah PP; Ghare S; Casson L; Wunderlich M; Siskind LJ; Beverly LJ
Cells; 2019 Oct; 8(11):. PubMed ID: 31717699
[TBL] [Abstract][Full Text] [Related]
10. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.
Yi Y; Ge S
J Hematol Oncol; 2022 Mar; 15(1):35. PubMed ID: 35331314
[TBL] [Abstract][Full Text] [Related]
11. The role of DOT1L in the maintenance of leukemia gene expression.
Wang X; Chen CW; Armstrong SA
Curr Opin Genet Dev; 2016 Feb; 36():68-72. PubMed ID: 27151433
[TBL] [Abstract][Full Text] [Related]
12. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
13. Mixed lineage leukemia: roles in human malignancies and potential therapy.
Marschalek R
FEBS J; 2010 Apr; 277(8):1822-31. PubMed ID: 20236311
[TBL] [Abstract][Full Text] [Related]
14. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
Anglin JL; Song Y
J Med Chem; 2013 Nov; 56(22):8972-83. PubMed ID: 23879463
[TBL] [Abstract][Full Text] [Related]
15. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
Bernt KM; Zhu N; Sinha AU; Vempati S; Faber J; Krivtsov AV; Feng Z; Punt N; Daigle A; Bullinger L; Pollock RM; Richon VM; Kung AL; Armstrong SA
Cancer Cell; 2011 Jul; 20(1):66-78. PubMed ID: 21741597
[TBL] [Abstract][Full Text] [Related]
16. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
17. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R; Lawrence CK; Lakowski TM
J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
[TBL] [Abstract][Full Text] [Related]
18. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L.
Basavapathruni A; Jin L; Daigle SR; Majer CR; Therkelsen CA; Wigle TJ; Kuntz KW; Chesworth R; Pollock RM; Scott MP; Moyer MP; Richon VM; Copeland RA; Olhava EJ
Chem Biol Drug Des; 2012 Dec; 80(6):971-80. PubMed ID: 22978415
[TBL] [Abstract][Full Text] [Related]
19. The molecular biology of mixed lineage leukemia.
Slany RK
Haematologica; 2009 Jul; 94(7):984-93. PubMed ID: 19535349
[TBL] [Abstract][Full Text] [Related]
20. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]